Conventional and Targeted Treatments: Limitations and Challenges
Standard treatment for early-stage cervical cancer includes radical hysterectomy or a combination of radiation therapy (RT) and chemotherapy. In metastatic cases, targeted therapies such as monoclonal antibodies and angiogenesis inhibitors have been explored. Unfortunately, these therapies have achieved only limited success. For example, although epidermal growth factor receptor (EGFR) is frequently overexpressed in cervical cancer and associated with poor outcomes, EGFR-targeting monoclonal antibodies like cetuximab have shown modest efficacy, especially as monotherapy.
Immunotherapy strategies, including therapeutic vaccines targeting HPV oncoproteins E6 and E7, have also shown limited clinical benefit due to immune evasion mechanisms like HLA downregulation. As a result, there is a growing interest in leveraging natural killer (NK) cells, which can recognize and kill cancer cells independently of HLA presentation.
The Promise of NK Cell-Based Therapy in Cervical Cancer
NK cells, central players in the innate immune system, possess a unique ability to identify and destroy tumour and virus-infected cells without prior sensitization. They operate through a finely tuned balance between activating (e.g., NKG2D, NKp30, NKp46) and inhibitory (e.g., NKG2A) receptors. Upon activation, NK cells secrete cytotoxic granules containing perforin and granzyme B, and produce cytokines such as IFN-γ and TNF-α, contributing to immune activation and tumour cell apoptosis.
Innovative therapies are focusing on NK cell-based immunotherapy, particularly using cells derived from umbilical cord blood (UCB), which is a non-invasive, readily available source. UCB-derived NK cells are appealing due to their allogeneic compatibility and potential as “off-the-shelf” products. However, their low initial numbers and immature functional state necessitate ex vivo expansion techniques to enhance their clinical utility.
Cytokine cocktails—such as IL-2, IL-15, IL-12, and IL-18—combined with artificial antigen-presenting cells have significantly improved NK cell yield and cytotoxic potential. Notably, UCB-derived CD34+ progenitor NK cells exhibit superior anti-tumour activity compared to peripheral blood-derived NK cells, especially against HLAdeficient tumour cells like cervical cancer.
Emerging Strategies: Genetic Modification and CAR-NK Cell Therapy
Advances in genetic engineering have enabled the development of chimeric antigen receptor (CAR) – modified NK cells. CARs targeting tumour-associated antigens like CD19 have shown success in hematologic malignancies and are now being adapted for solid tumours, including cervical cancer. UCB-derived NK cells engineered with CAR constructs (e.g., NKG2D-DAP10-CD3ζ) demonstrate enhanced tumour cytotoxicity in preclinical models.
Inhibitory checkpoint modulation is another promising strategy. UCB-derived NK cells typically express higher levels of NKG2A, a receptor that suppresses NK cell activity. Blocking NKG2A with monoclonal antibodies or using CAR constructs to override this inhibition could significantly enhance the therapeutic efficacy of NK cell-based treatments in cervical cancer.
MSC-Based Approaches: Tumour Homing and Exosome Therapy
Mesenchymal stem cells (MSCs), particularly those derived from the umbilical cord (UCMSCs), have emerged as potent anti-cancer agents. Owing to their innate tumour-homing capabilities, MSCs can be engineered to deliver therapeutic payloads directly to tumour sites, minimizing systemic toxicity.
Recent studies have shown that UCMSC-derived exosomes, particularly those containing miR-15a-5p, can inhibit epithelial-to-mesenchymal transition (EMT) and suppress metastasis in cervical cancer models. Additionally, conditioned medium and cellular extracts from UCMSCs have demonstrated anti-proliferative and pro-apoptotic effects on cervical cancer cell lines such as HeLa.
Furthermore, innovations in biocompatible nanocarriers are being explored to deliver MSC-engineered therapies and exosomal cargoes more effectively to tumours. Clinical trials are now examining UCMSCs both as therapeutic agents and as vectors for targeted anti-cancer gene delivery.
New Innovations in Stem Cell and NK-Based Research Since 2023
Since 2023, key advancements include:
- CAR-NK cells targeting HPV antigens: Novel CAR constructs specific to HPV oncoproteins E6/E7 are being tested, showing selective cytotoxicity in cervical cancer models.
- iPSC-derived NK cells: Induced pluripotent stem cell (iPSC)-derived NK cells offer scalable, renewable NK cell sources with customizable receptor expression, including CARs, for personalized therapies.
- Organoid and 3D-bioprinted tumour models: These systems are now being used to evaluate stem cell therapies in a patient-specific manner, increasing translational relevance and optimizing therapeutic dosing.
- Exosome engineering: Recent progress in loading exosomes with therapeutic microRNAs, small interfering RNAs (siRNAs), and immune modulators is expanding the application of UCMSC-derived vesicles in oncology.
- Checkpoint blockade with NK cells: Studies are investigating combination therapies of UCB-NK cells with checkpoint inhibitors like anti-NKG2A or anti-PD-L1 for enhanced tumour killing in cervical cancer.
Recent advances in stem cell research have opened promising avenues for the treatment of cervical cancer, particularly through the use of mesenchymal stem cells (MSCs), extracellular vesicles, and engineered immune cell therapies.
- Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles (hUCMSC-EVs)
Recent studies have highlighted the tumor-suppressive effects of extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells (hUCMSCs). These EVs, particularly small extracellular vesicles (sEVs), have been shown to carry microRNAs like miR-370-3p, which directly target and downregulate oncogenes such as DHCR24, thereby inhibiting the development of cervical precancerous lesions. Additionally, another study demonstrated that hUCMSC-derived sEVs can suppress inflammation and modulate the tumor microenvironment to reduce the risk of cervical cancer progression
- Chimeric Antigen Receptor (CAR) NK Cell Therapy
Engineering natural killer (NK) cells with chimeric antigen receptors (CARs) represents a significant innovation in immunotherapy. A 2024 study reported the successful generation of CAR-NK cells targeting mesothelin, a protein commonly overexpressed in cervical cancer. These CAR-NK cells demonstrated potent cytotoxicity against cervical cancer cells in both 2D and 3D models. When combined with chemotherapeutic agents such as cisplatin, the therapeutic effect was significantly enhanced compared to monotherapy.
- iPSC-Derived Rejuvenated Cytotoxic T Lymphocytes
Induced pluripotent stem cells (iPSCs) have been employed to generate rejuvenated cytotoxic T lymphocytes (rejTs) specifically engineered to target HPV-related antigens such as E6 and E7, which are expressed in cervical cancer cells. These rejTs provide a personalized and robust immune response, potentially overcoming the limitations of traditional T-cell therapies which are often impeded by HLA downregulation in cervical tumors. The development of this technology marks a significant step forward in adoptive cellular immunotherapy for HPV-induced cervical cancers (News-Medical.net, 2024, https://www.news-medical.net/news/20240305/Scientists-develop-robust-iPSC-derived-rejuvenated-T-lymphocytes-for-cervical-cancer-treatment.aspx).
- Microbiome Influence on Cervical Stem Cells
A novel study published in Nature Communications (2025) explored how metabolites from cervical microbiota can influence cervical stem cell biology. The researchers found that D-lactic acid, a byproduct of Lactobacillus metabolism, suppresses the proliferation of cervical organoids—including both normal and precancerous cells—by modulating PI3K-AKT and YAP1 signaling pathways. This finding suggests that manipulating the microbiome could serve as a preventive strategy against cervical cancer by targeting early stem cell transformation.
- Engineered Mesenchymal Stem Cells for Targeted Cancer Therapy
MSCs have been increasingly engineered to act as delivery vehicles for anti-cancer agents, leveraging their natural tumor-homing abilities. These modified MSCs have been loaded with pro-apoptotic proteins, chemotherapeutic agents, and even oncolytic viruses to enhance therapeutic specificity and reduce systemic toxicity. A 2025 review highlights their utility in delivering targeted therapies directly to cervical tumors, offering both localized treatment and a reduction in metastasis.
In summary, stem cell-based therapies, including hUCMSC-derived EVs, CAR-NK cells, iPSC-rejuvenated T cells, microbiome-stem cell interactions, and genetically modified MSCs, are rapidly evolving into powerful tools for treating cervical cancer. These emerging technologies provide a foundation for future therapies that may overcome the limitations of conventional treatment and improve outcomes for patients globally.
Conclusion
Stem cell-based and NK cell-based immunotherapies offer transformative potential in the fight against cervical cancer. UCB-derived NK cells, particularly when genetically engineered, have shown strong preclinical efficacy and are progressing toward clinical translation. In parallel, UCMSCs and their exosomes present a multifaceted therapeutic platform that can inhibit tumour progression and enhance immune responses. As research continues to refine expansion protocols, delivery systems, and genetic modification strategies, these cell-based therapies are poised to become central components of future cervical cancer treatment.
